Vitarka Therapeutics

Founded in 2021 by Dr. Vineeta Tripathi, Vitarka Therapeutics Ltd is based in Sandwich, Kent, UK at the Discovery Park innovation campus. The company is addressing the endosomal entrapment problem — a key barrier to intracellular drug delivery — through its proprietary EndoPore platform, which uses pore-forming proteins to deliver small interfering RNA (siRNA) drugs directly to intracellular targets in tumor cells. Unlike antibody-drug conjugates (ADCs), EndoPore's dual mechanism of tumor selectivity limits toxicity to normal tissue and avoids linker instability issues. Vitarka raised £1.27 million (~$1.58M USD) in 2023 from SOSV's IndieBio accelerator and has presented at RNA therapeutics and oncology conferences. The company targets late-stage cancers where existing delivery technologies fail.